Gastric cancer - combination treatment with a platinum based regimen

Active Ingredient: Capecitabine

Indication for Capecitabine

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Capecitabine is indicated for the treatment of first-line treatment of advanced gastric cancer in combination with a platinum based regimen.

For this indication, competent medicine agencies globally authorize below treatments:

800-1000 mg/m² twice daily for 14 days followed by a 7-day rest period, or 625 mg/m² twice daily when administered continuously

For:

Dosage regimens

Regimen A

Oral, between 800 milligrams capecitabine per square meter of body surface and 1,000 milligrams capecitabine per square meter of body surface, 2 times daily to meals, 28 doses in total, over the duration of 21 days.

Regimen B

Oral, 625 milligrams capecitabine per square meter of body surface, 2 times daily to meals, over the duration of 21 days.

Detailed description

In combination treatment, the recommended starting dose of capecitabine should be reduced to 800-1000 mg/m² when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m² twice daily when administered continuously. For combination with irinotecan, the recommended starting dose is 800 mg/m² when administered twice daily for 14 days followed by a 7-day rest period combined with irinotecan 200 mg/m² on day 1. The inclusion of bevacizumab in a combination regimen has no effect on the starting dose of capecitabine. Premedication to maintain adequate hydration and anti-emesis according to the cisplatin summary of product characteristics should be started prior to cisplatin administration for patients receiving the capecitabine plus cisplatin combination. Premedication with antiemetics according to the oxaliplatin summary of product characteristics is recommended for patients receiving the capecitabine plus oxaliplatin combination.

Dosage considerations

It should be taken with water within 30 minutes after a meal.

Active ingredient

Capecitabine

Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). Capecitabine is activated via several enzymatic steps.

Read more about Capecitabine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.